

# Genetic Analysis for acquired (somatic) Leukaemia-associated Mutations

Prof. Dr. J. Skokowa/Prof. Dr. K. Welte  
Med Klinik II  
University Hospital Tuebingen  
Bettenbau West (501), Eb. 02, Raum 532  
Otfried-Mueller-Str. 10  
72076 Tuebingen, Germany

Patient:  Date of Birth:

Patient is registered in the SCNIR:  Yes  No

### Clinical Diagnosis:

Congenital Neutropenia  Cyclic Neutropenia  Other:

Somatic Panel Analysis:  Primary  Follow-up  Analysis is urgent\*(*Consultation required*)

\*Reason for urgen analysis:  Abnormal cytogenetics  Abnormal morphology  Other:

Previous G-CSFR analyses:  Yes:  positive  negative  No

### Previous results of molecular genetic tests:

<input type="checkbox"/> ELANE	<input type="checkbox"/> HAX 1	<input type="checkbox"/> G6PC3	<input type="checkbox"/> SBDS	<input type="checkbox"/> other: <input type="text"/>
<input type="checkbox"/> positive	<input type="checkbox"/> positive	<input type="checkbox"/> positive	<input type="checkbox"/> positive	<input type="checkbox"/> positive
<input type="checkbox"/> negative	<input type="checkbox"/> negative	<input type="checkbox"/> negative	<input type="checkbox"/> negative	<input type="checkbox"/> negative
<input type="checkbox"/> not tested	<input type="checkbox"/> not tested	<input type="checkbox"/> not tested	<input type="checkbox"/> not tested	<input type="checkbox"/> not tested

Therapy: G-CSF:  Yes  No  Other:

### Clinical Findings:

Sample:  1 - 5 ml Heparinized Bone Marrow  10 - 20 ml Heparinized Peripheral Blood

Date Drawn:

Sender (*please print or stamp*):

### Consent according to the German law for genetic testing (Gen DG)

#### Consent of the Patient / Legal Guardian

The storage of residual material as well as the use of residual specimen for research purpose. Data will be pseudonymized. The research includes studies on how genetic mutations may contribute to the development of leukaemia or other types of cancer. Even if no cancer is present or does not occur later in life, the material is helpful. I agree that the results will be stored for more than the legal period of ten years.

Location, Date

Signature of the Patient /  
legal Guardian

Signature of Responsible Physician

*Samples should be taken at the beginning of the week (Monday or Tuesday)  
and sent off immediately by overnight express!*

**Please notify the laboratory prior to sending the sample:**

Phone: +49 7071 2986014 or +49 162 2052224; Fax: +49 7071 2925161

email: [Labor-SCNIR@med.uni-tuebingen.de](mailto:Labor-SCNIR@med.uni-tuebingen.de)

**Additional information:**

**List of regions/genes included in the panel:**

	<b>Gene names</b>
Sequencing of the entire protein-coding regions (n = 29)	<i>ASXL1, ASXL2, BCOR, BCORL1, CBL, CEBPA, CSF3R, DDX41, DNMT3A, ETV6, EZH2, KIT, KMT2D, KRAS, NF1, NPM1, NRAS, PHF6, PTPN11, RAD21, RUNX1, SETBP1, SRSF2, STAG2, TET2, TP53, U2AF1, WT1, ZRSR2</i>
Sequencing of hotspot regions in leukemia-associated genes (n = 16). The DNA positions (mutated in at least 2-3 cancer patients) were selected using the whole exome and whole genome sequencing records of 9863 leukemia and MDS samples (9569 patients) in 10 studies. A detailed description of datasets is available at <a href="https://bit.ly/3XX8iKv">https://bit.ly/3XX8iKv</a> . Genomic coordinates are available on request.	<i>ATM, CTCF, EP300, ETNK1, FLT3, GATA1, GATA2, IDH1, IDH2, JAK2, MPL, SF3B1, SMC1A, SMC3, SRCAP, SUZ12</i>